Andrew Singer Net Worth & Insider Trades
Andrew Singer - EVP & CFO, Epizyme, Inc
What is Andrew Singer's Net Worth?
The current estimated net worth of Epizyme, Inc's EVP & CFO, Andrew Singer, is estimated to be about $346.95K . Andrew Singer owns about 40,529 units of Epizyme, Inc common stock. In the last 2 years at Epizyme, Inc, Andrew Singer has sold an estimated value of $325.44K worth.
What is Andrew Singer's Past Insider Trading?
Andrew Singer's largest sale order was 12,158 units , worth over $115.99K on February 10, 2016. In total, Andrew Singer has made about 23 transactions over 2 years of their time at Epizyme, Inc. Andrew Singer usually trades in July, May, February and April, with the busiest year in 2016. The most recent transaction was a sale order of 3,024 units , worth over $46.87K on July 5, 2017.
Andrew Singer
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Andrew Singer's' Mailing Address?
- Mailing address is C/o Epizyme, Inc. 400 Technology Square, 4th Floor Cambridge MA 02139 MA
Epizyme, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Restricted Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Robert B. Bazemore Jr. | 2020 | $650,000 | - | $3,237,620 | $4,103,853 | $370,500 | $96,369 | $8,458,342 |
| Robert B. Bazemore Jr. | 2019 | $592,937 | - | $1,105,393 | $2,060,531 | $409,127 | $5,630 | $4,173,618 |
| Robert B. Bazemore Jr. | 2018 | $575,667 | - | - | $2,748,939 | $320,575 | $5,690 | $3,650,871 |
| Paolo Tombesi | 2020 | $460,000 | - | $250,006 | $750,730 | $174,800 | $48,198 | $1,683,734 |
| Paolo Tombesi | 2019 | $168,901 | - | $612,848 | $1,173,669 | $76,076 | $146,971 | $2,178,465 |
| Matthew E. Ros | 2020 | $447,982 | - | $250,006 | $750,730 | $174,800 | $11,271 | $1,634,789 |
| Matthew E. Ros | 2019 | $432,600 | - | $538,793 | $899,137 | $199,861 | $11,598 | $2,081,989 |
| Matthew E. Ros | 2018 | $420,000 | - | - | $1,099,576 | $187,100 | $12,214 | $1,718,890 |
| Dr. Shefali Agarwal | 2020 | $478,000 | - | $274,990 | $825,799 | $199,804 | $7,154 | $1,785,747 |
| Dr. Shefali Agarwal | 2019 | $463,500 | - | $894,607 | $1,255,325 | $265,122 | $8,652 | $2,887,206 |
| Dr. Shefali Agarwal | 2018 | $199,615 | $125,000 | - | $1,472,846 | $200,500 | $1,648 | $1,999,609 |
| Jeffery L. Kutok, M.D., Ph.D. | 2020 | $337,500 | $85,000 | $374,996 | $1,124,996 | $134,663 | $6,813 | $2,063,968 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1571498/000119312521138283/d839557ddef14a.htm
What are Epizyme, Inc's Past Insider Trades?
Epizyme, Inc's most recent insider trade came on April 13, 2022 by Jeffery Kutok who sold 2,741 units worth $2.47K . In the last 9 years, insiders at Epizyme, Inc have sold an estimated value of $156.28M and bought an estimated value of $381.12M worth of shares. Insider trading is most common in June, with the busiest year in 2014. The most active traders at the company are David Mott, Director, Robert Copeland, President Research and CSO, and Andrew Singer, EVP & CFO .
Epizyme, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||